Subscribe to the Voices in Health Care Value newsletter to be notified about new research, policies, and upcoming events relevant to the health care value community.
Archive of Previous Voices in Health Care Value
Welcome to the third issue of Voices in Health Care Value, the newsletter of the Research Consortium for Health Care Value Assessment (RC-HCVA). This issue highlights work from our colleagues at the Center for Enhanced Value Assessment (CEVA). We appreciate your comments and inputs to subsequent issues. If you are interested in becoming a Colleague in Value (individuals and groups who work in this area or who are simply interested in its findings) please register here.
PhRMA Foundation Funds Two New Centers of Excellence in Value Assessment
By George Miller, Altarum
The Research Consortium for Health Care Value Assessment is one of two national Centers of Excellence in Value Assessment established in 2018 by the PhRMA Foundation. (The other is the University of Maryland’s Patient-Driven Values in Healthcare Evaluation (PAVE). The foundation recently announced the creation of two additional Centers of Excellence.
Tufts Medical Center has established the Center for Enhanced Value Assessment (CEVA). CEVA is led by Peter J. Neumann, ScD, Director of Tufts’ Center for the Evaluation of Value and Risk in Health (CEVR), which is our featured “Colleague in Value” in this month’s newsletter (see article below). The standard metric used in traditional cost-effectiveness analysis is the cost pre quality-adjusted life year (QALY). CEVA will explore development of additional elements of value that extend beyond the cost per QALY, based in part on inputs from patients, clinicians, and other stakeholders. The center will also develop infrastructure that supports future work in use of such non-standard value elements in cost-effectiveness analyses.
The Center for Pharmaceutical Value (PValue) at the University of Colorado is directed by Jonathan D. Campbell, PhD. PValue is building on prior research to investigate the use of multicriteria decision analysis in support of decision making regarding pharmaceutical coverage (what drugs are included in an insurance benefit) and reimbursement (rules for payment for use of the drugs). Experiments will be designed to test the benefits of such decision tools in supporting transparency, consistency, and fairness in pharmaceutical coverage and reimbursement decisions.
We welcome these two new centers to the family of Centers of Excellence in Value and look forward to seeing the results of their research and to the possibility of collaborative efforts with them.
Each issue will spotlight work by a Colleague in Value. This issue’s spotlight is on the Center for Enhanced Value Assessment (CEVA). CEVA’s Anna Legassie provided this information.
The Center for the Evaluation of Value and Risk in Health (CEVR)
As a recent PhRMA Center of Excellence Award winner, The Center for the Evaluation of Value and Risk in Health (CEVR) at Tufts Medical Center in Boston, MA will develop a new program called the Center for Enhanced Value Assessment (CEVA), led by principal investigator Peter J. Neumann, ScD. CEVA’s mission is to explore the quantitative incorporation of novel elements of value into traditional cost-effectiveness analysis.
Since its founding in 2006, CEVR has emerged as a leader in value assessment and aims to analyze “the benefits, risks, and costs of strategies to improve health and health care.” In addition to authoring many influential research papers and commentaries, CEVR has developed the Cost-Effectiveness Analysis (CEA) Registry, the largest repository of standardized information on such analyses, with more than 6,000 published cost-effectiveness analyses and 17,000 cost-effectiveness ratios.
Supported by the Center for Excellence Award, CEVA will conduct a literature review using the Tufts CEA registry to assess how often studies report enhanced value assessment elements such as productivity losses and caregiver costs, engage patients and stakeholders to identify those elements that are most important to their experience, augment existing analyses by incorporating these elements, and report findings back to stakeholders. CEVA will support future work by developing tools and publicly available resources to improve consistency across health technology assessments (HTAs).
These organizations engage in the process of identifying and finding ways to reduce the use of low-value care services in their target areas. For more information on these organizations and some of their findings please follow the links below:
The purpose of the RC-HCVA symposium is to bring together our Colleagues in Value to discuss relevant research areas, challenges to implementation, and gaps in what end-users need to inform policy change regarding value in health care. The 2018 Symposium Report can be found here. More information on the 2019 Symposium event will be available shortly. If you are interested in attending, please send an email to firstname.lastname@example.org.
Sign up for Voices in Health Care Value
The Research Consortium for Health Care Value Assessment is a partnership between Altarum and VBID Health, with funding from the PhRMA Foundation as part of its Value Assessment Initiative, established to promote the pursuit of value in health care delivery in the U.S. Follow us at @ValueConsortium.